Sugi Predict

Sugi Predict / Compounds / SCHEMBL274890

SCHEMBL274890

SCHEMBL274890

Nc1ccc(CN2CCN(C3CC3)CC2)c(C(F)(F)F)c1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.69
▸ KDM4E B2RXH2 3/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ ATM Q13315 1/20 0.43
▸ CHRM1 P11229 4/20 0.41
▸ TRPV6 Q9H1D0 3/20 0.41
▸ DDR1 Q08345 1/20 0.41
▸ DRD2 P14416 1/20 0.40
▸ POLB P06746 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ ACHE P22303 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29958956 1.00 NR1H2 (0.69) NR1H2KDM4EALDH1A1ATMCHRM1
SCHEMBL24192809 0.95 NR1H2 (0.66) NR1H2KDM4EALDH1A1ATMCHRM1
SCHEMBL27088110 0.88 NR1H2 (0.64) NR1H2KDM4EALDH1A1ATMDDR1
SCHEMBL24192814 0.86 NR1H2 (0.58) NR1H2KDM4EALDH1A1DDR1GAA
SCHEMBL15690007 0.84 NR1H2 (0.69) NR1H2KDM4EALDH1A1ATMPOLB
SCHEMBL545052 0.83 NR1H2 (0.76) NR1H2KDM4EALDH1A1ATMDDR1
SCHEMBL4933173 0.83 NR1H2 (0.76) NR1H2KDM4EALDH1A1ATMDRD2
SCHEMBL15688033 0.83 NR1H2 (0.60) NR1H2KDM4EALDH1A1ATMCHRM1
SCHEMBL22684866 0.82 NR1H2 (0.71) NR1H2KDM4EALDH1A1ATMDRD2
SCHEMBL27088097 0.82 NR1H2 (0.67) NR1H2KDM4EALDH1A1ATMDDR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122857-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2012-05-17 — — US claimed
US-20100113467-A1 Organic Compounds NOVARTIS AG 2010-05-06 — — US claimed
EP-2146964-A2 ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE Novartis Ag (CH) 2010-01-27 — — EP claimed
EP-1996558-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES Novartis AG (CH) 2008-12-03 — — EP claimed
WO-2008125691-A2 ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE NOVARTIS AG (CH) 2008-10-23 — — WO claimed
WO-2007104538-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2007-09-20 — — WO claimed
US-20250177382-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2025-06-05 — — US disclosed
US-20240317758-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-09-26 — — US disclosed
EP-4320127-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-02-14 — — EP disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
WO-2022216680-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2022-10-13 — — WO disclosed
EP-2371822-A1 Heterobicyclic carboxamides as inhibitors for kinases Novartis AG (CH) 2011-10-05 — — EP disclosed
US-7855215-B2 Cyclic diaryl ureas suitable as tyrosine kinase inhibitors NOVARTIS AG (CH) 2010-12-21 — — US disclosed
US-20100113467-A1 Organic Compounds NOVARTIS AG 2010-05-06 — — US disclosed
US-20100029626-A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers NOVARTIS AG (CH) 2010-02-04 — — US disclosed
EP-2146964-A2 ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE Novartis Ag (CH) 2010-01-27 — — EP disclosed
WO-2008125691-A2 ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE NOVARTIS AG (CH) 2008-10-23 — — WO disclosed
US-20080039440-A1 Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors BOLD GUIDO 2008-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029626-A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers SLC8B1, MCU, GLS NR1H2 3262/4885KDM4E 3893/4885ALDH1A1 2955/4885
US-20080039440-A1 Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors RET, ROS1, BRAF NR1H2 675/4885KDM4E 1694/4885ALDH1A1 2149/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 NR1H2 2488/4885KDM4E 4052/4885ALDH1A1 4542/4885
US-20100113467-A1 Organic Compounds SLCO2A1, SLCO1B1, SLCO2B1 NR1H2 440/4885KDM4E 3875/4885ALDH1A1 68/4885
US-20250177382-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 NR1H2 1673/4885KDM4E 3092/4885ALDH1A1 3958/4885
US-20240317758-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 NR1H2 2147/4885KDM4E 2804/4885ALDH1A1 4225/4885
US-20120122857-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES MAP3K20, PHKG1, PHKG2 NR1H2 3256/4885KDM4E 1717/4885ALDH1A1 4102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.